Clinicians' recognition of the metabolic adverse effects of antipsychotic medications

Peter F Buckley, Del D. Miller, Beth Singer, John Arena, Edna M. Stirewalt

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

There is a growing concern regarding the propensity of second generation antipsychotics (SGAs) to induce weight gain and metabolic adverse effects. Recent consensus guidelines have recommended assessment and monitoring procedures to appropriately detect and manage these adverse effects. This study addresses the appreciation and readiness of clinicians to implement management guidelines for these adverse effects. Respondents indicated awareness of the risks of treatment with SGAs. The extent of monitoring for metabolic adverse effects was low and inconsistent across measures and in frequency of evaluation. Ongoing efforts are needed to support and encourage change in clinician practice.

Original languageEnglish (US)
Pages (from-to)281-288
Number of pages8
JournalSchizophrenia Research
Volume79
Issue number2-3
DOIs
StatePublished - Nov 15 2005

Fingerprint

Antipsychotic Agents
Guidelines
Weight Gain
Surveys and Questionnaires

Keywords

  • Antipsychotics
  • Diabetes mellitus
  • Metabolic complications
  • Weight gain

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Buckley, P. F., Miller, D. D., Singer, B., Arena, J., & Stirewalt, E. M. (2005). Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophrenia Research, 79(2-3), 281-288. https://doi.org/10.1016/j.schres.2005.04.010

Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. / Buckley, Peter F; Miller, Del D.; Singer, Beth; Arena, John; Stirewalt, Edna M.

In: Schizophrenia Research, Vol. 79, No. 2-3, 15.11.2005, p. 281-288.

Research output: Contribution to journalArticle

Buckley, PF, Miller, DD, Singer, B, Arena, J & Stirewalt, EM 2005, 'Clinicians' recognition of the metabolic adverse effects of antipsychotic medications', Schizophrenia Research, vol. 79, no. 2-3, pp. 281-288. https://doi.org/10.1016/j.schres.2005.04.010
Buckley, Peter F ; Miller, Del D. ; Singer, Beth ; Arena, John ; Stirewalt, Edna M. / Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. In: Schizophrenia Research. 2005 ; Vol. 79, No. 2-3. pp. 281-288.
@article{6c7414b6942b4b9097f60550d56ea4c6,
title = "Clinicians' recognition of the metabolic adverse effects of antipsychotic medications",
abstract = "There is a growing concern regarding the propensity of second generation antipsychotics (SGAs) to induce weight gain and metabolic adverse effects. Recent consensus guidelines have recommended assessment and monitoring procedures to appropriately detect and manage these adverse effects. This study addresses the appreciation and readiness of clinicians to implement management guidelines for these adverse effects. Respondents indicated awareness of the risks of treatment with SGAs. The extent of monitoring for metabolic adverse effects was low and inconsistent across measures and in frequency of evaluation. Ongoing efforts are needed to support and encourage change in clinician practice.",
keywords = "Antipsychotics, Diabetes mellitus, Metabolic complications, Weight gain",
author = "Buckley, {Peter F} and Miller, {Del D.} and Beth Singer and John Arena and Stirewalt, {Edna M.}",
year = "2005",
month = "11",
day = "15",
doi = "10.1016/j.schres.2005.04.010",
language = "English (US)",
volume = "79",
pages = "281--288",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Clinicians' recognition of the metabolic adverse effects of antipsychotic medications

AU - Buckley, Peter F

AU - Miller, Del D.

AU - Singer, Beth

AU - Arena, John

AU - Stirewalt, Edna M.

PY - 2005/11/15

Y1 - 2005/11/15

N2 - There is a growing concern regarding the propensity of second generation antipsychotics (SGAs) to induce weight gain and metabolic adverse effects. Recent consensus guidelines have recommended assessment and monitoring procedures to appropriately detect and manage these adverse effects. This study addresses the appreciation and readiness of clinicians to implement management guidelines for these adverse effects. Respondents indicated awareness of the risks of treatment with SGAs. The extent of monitoring for metabolic adverse effects was low and inconsistent across measures and in frequency of evaluation. Ongoing efforts are needed to support and encourage change in clinician practice.

AB - There is a growing concern regarding the propensity of second generation antipsychotics (SGAs) to induce weight gain and metabolic adverse effects. Recent consensus guidelines have recommended assessment and monitoring procedures to appropriately detect and manage these adverse effects. This study addresses the appreciation and readiness of clinicians to implement management guidelines for these adverse effects. Respondents indicated awareness of the risks of treatment with SGAs. The extent of monitoring for metabolic adverse effects was low and inconsistent across measures and in frequency of evaluation. Ongoing efforts are needed to support and encourage change in clinician practice.

KW - Antipsychotics

KW - Diabetes mellitus

KW - Metabolic complications

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=26844540967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844540967&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2005.04.010

DO - 10.1016/j.schres.2005.04.010

M3 - Article

VL - 79

SP - 281

EP - 288

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 2-3

ER -